کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1397891 | 1501194 | 2009 | 6 صفحه PDF | دانلود رایگان |

In this work, marketed drug compounds (or known drug space) were used as a metric to test the principles of eliminating parent structures of the nitrenium ion (aryl-amine/nitro compounds) as well as sulphur and halogen containing molecules from screening compound collections. Molecules containing such moieties and/or atoms have biological and physiochemical properties, which possibly make them less attractive as leads in drug development. It was found that precursors to the nitrenium ion were relatively abundant in known drug space at 14%. Thus, their simple elimination from drug-like chemical space is not advisable. Interestingly, the mutagenic potential of the nitrenium ions is linked to their stability and quantum mechanical calculations can be used to estimate it. Furthermore, 24% of drugs investigated contained sulphur atoms and around 28% were halogenated. As some sulphur containing moieties were abundant whilst others were scarce, it was deduced that it would be more effective to eliminate specific molecular scaffolds rather than all sulphur containing molecules. In conclusion, it has been shown that by statistically analysing known drug space a better understanding of the boundaries of drug-like chemical space was established which can help medicinal chemists in finding rewarding regions of chemical space.
A simple graphical representation of drug-like chemical space defined by molecular descriptors and “undesirable” moieties. In this study it was investigated whether nitro/amine-aryl moieties and sulphur/halogen containing molecules should be included in drug-like chemical space? This was done by statistically analysing known drug space. It was found that parent compounds of nitrenium ions should not be simply eliminated but analysed in more detail using, e.g., quantum mechanical calculations. Similarly, sulphur-containing compounds should not be eliminated and exclusion from drug-like chemical space should be based on “undesirable” moieties. Figure optionsDownload as PowerPoint slide
Journal: European Journal of Medicinal Chemistry - Volume 44, Issue 12, December 2009, Pages 5006–5011